Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» apalutamide
apalutamide
J&J gets first-of-its-kind prostate cancer approval
Biopharma Dive
Wed, 02/14/18 - 11:48 pm
JNJ
apalutamide
prostate cancer
As CAR-Ts go from candidates to brands, what's the marketing strategy?
Medical Marketing and Media
Tue, 02/13/18 - 09:01 am
CAR-T
drug marketing
JCAR017
Juno Therapeutics
Celgene
bb2121
Bluebird Bio
apalutamide
Janssen
Strong data lift profile of J&J's cancer drug apalutamide
Biopharma Dive
Tue, 02/6/18 - 11:45 am
JNJ
apalutamide
prostate cancer
With Pfizer in hot pursuit, J&J loses a critical patent fight as it scrambles for a new prostate cancer drug OK
Endpoints
Thu, 01/18/18 - 10:00 am
Pfizer
JNJ
patents
Zytiga
Xtandi
prostate cancer
apalutamide
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
Endpoints
Sun, 12/17/17 - 11:47 am
drug launches
Bictegravir/F/TAF
Gilead Sciences
semaglutide
Novo Nordisk
epacadostat
Incyte
Rova-T
AbbVie
ozanimod
Celgene
apalutamide
JNJ
Elagolix
AVXS-101
AveXis
lanadelumab
Shire
Epidiolex
GW Pharma
J&J takes another big step forward with next-gen prostate cancer blockbuster apalutamide
Endpoints
Thu, 10/12/17 - 09:16 am
JNJ
prostate cancer
apalutamide
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
Motley Fool
Sun, 07/23/17 - 11:47 am
Biogen
aducanumab
JNJ
apalutamide
Eli Lilly
abemaciclib
AbbVie
Rova-T
Celgene
ozanimod